Neuralgia Clinical Trials

Find Neuralgia Clinical Trials Near You

Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study (PINCom)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Complex Regional Pain Syndrome (CRPS) is a chronic pain condition characterized by severe regional pain, sensory disturbances, and functional impairment. Current treatment options are limited, and many patients experience substantial pain-related disability and symptom fluctuations, including flare-ups triggered by invasive procedures. Perineural administration of botulinum toxin A has shown analgesic effects in other neuropathic pain conditions and may represent a less painful alternative to subcutaneous injection techniques. However, the feasibility, tolerability, and safety of perineural botulinum toxin administration in patients with CRPS have not been systematically evaluated. The PINCom study is a single-center, open-label feasibility study designed to assess the safety, tolerability, and practical feasibility of ultrasound-guided perineural injection of incobotulinumtoxin-A in patients with unilateral chronic CRPS affecting an upper or lower limb. Participants receive a single perineural injection targeting major sensory nerves supplying the affected limb and are followed for 12 weeks. Primary outcomes focus on feasibility metrics, including recruitment, retention, adherence, and data completeness, as well as safety outcomes, including serious adverse events and procedure-related complications. Tolerability is assessed through monitoring of CRPS flare-ups and a dedicated qualitative interview exploring participant experience. Exploratory outcomes include pain intensity, CRPS severity, and patient-reported measures collected to inform the design of a future randomized controlled trial.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Are over the age of 18

• Have a diagnosis of CRPS type 1 or 2 in either one upper or one lower extremity which fulfils the Budapest research criteria

• Have had the condition for at least 6 months

• Rate CRPS as their primary pain condition

• Have been on a stable analgesic regimen, including any rescue medications, for at least 1 month prior to the study and intend to maintain this regimen throughout the study

• For pre-menopausal females: are using a safe and approved contraceptive

• Speak, read, and understand Danish

Locations
Other Locations
Denmark
CRPS- and Nerve Pain Clinic, Rigshospitalet Glostrup
RECRUITING
Glostrup
Contact Information
Primary
Marc K Olsen, MD
marc.klee.olsen@regionh.dk
+45 38633030
Time Frame
Start Date: 2026-01-07
Estimated Completion Date: 2026-08-01
Participants
Target number of participants: 20
Treatments
Experimental: Active
Open-label treatment with 200 U of perineural Xeomin, either around the brachial plexus or the distal ischial and saphenus nerves.
Sponsors
Collaborators: Merz Pharmaceuticals GmbH, The GCP unit at Copenhagen University Hospital
Leads: Bo Biering-Soerensen

This content was sourced from clinicaltrials.gov